Study of the Inappropriate Secretion of FGF23 in Patients Followed in Hospital in a Context of Hypophosphatemia

Study of the Inappropriate Secretion of FGF23 in Patients Followed in Hospital in a Context of Hypophosphatemia

Sponsors

Lead Sponsor: University Hospital, Clermont-Ferrand

Collaborator: DiaSorin ; Saluggia, Italia

Source University Hospital, Clermont-Ferrand
Brief Summary

The discovery of FGF23, the missing link in the long researched and finally found phosphate metabolism, marked a turning point in the understanding and physiopathology of specific hypophosphatemia. By inhibiting the renal reabsorption of phosphate and the production of calcitriol, FGF23 behaves like a hypophosphatemia hormone. Hypersecretion of FGF23 can occur in the case of genetic abnormalities (X-linked hypophosphatemic vitamin-resistant rickets, recessive or dominant hypophosphatemic rickets, McCune-Albright syndrome ...) or acquired abnormalities (oncogenic osteomalacia). Oncogenic osteomalacia can be induced by hyperproduction of FGF23 by benign tumours of mesenchymal origin. But more recently, several cases of malignant tumours secreting FGF23 have also been described (prostate, colon, breast, ovarian and lung cancers, pulmonary carcinoma, etc.)

Detailed Description

To date, even if the incidence of FGF23-secreting tumours seems rare, no precise bibliographical data is available in the scientific literature. Future studies will have to address this issue in order not to underestimate the frequency of this complication. In this context, investigators would like to study the incidence of inappropriate FGF23 increase from a collection of biological samples carried out on 500 patients treated at the Clermont-Ferrand University Hospital for hypophosphatemia.

Overall Status Not yet recruiting
Start Date 2021-09-01
Completion Date 2022-06-01
Primary Completion Date 2021-12-01
Study Type Observational
Primary Outcome
Measure Time Frame
Evaluate the frequency of blood levels of FGF23 unsuitable for hypophosphatemia day 0
Secondary Outcome
Measure Time Frame
Investigate the relationship between blood levels of FGF23 and other biochemical parameters in hospital patients with hypophosphatemia.. Day 1
Investigate the relationship between blood levels of FGF23 and other biochemical parameters in hospital patients with hypophosphatemia. day 1
Enrollment 500
Condition
Intervention

Intervention Type: Behavioral

Intervention Name: unexplained hypophoshatemia

Description: Collection of additional blood volume (approximately 10 mL) during blood tests provided as part of the usual medical care.

Arm Group Label: Unexplained hypophosphatemia

Eligibility

Sampling Method:

Non-Probability Sample

Criteria:

Inclusion Criteria: - Major patient, male or female - Taken care of at the Clermont-Ferrand University Hospital or the Jean Perrin Centre - In a context of hypophosphatemia (< 0.80 mmol/L), without immediate anteriority and not occurring during hospitalisation - In capacity to express informed consent to participate in research - Affiliated to a social security system Exclusion Criteria: - Previously diagnosed hypophosphatemia - Hypophosphatemia during hospitalisation - Haemodialysis patient - Refusal to participate

Gender:

All

Minimum Age:

18 Years

Maximum Age:

N/A

Healthy Volunteers:

Accepts Healthy Volunteers

Overall Official
Last Name Role Affiliation
Damien BOUVIER Principal Investigator University Hospital, Clermont-Ferrand
Overall Contact

Last Name: Lise Laclautre

Phone: 334.73.754.963

Email: [email protected]

Location
Facility: Contact: Investigator:
Chu Clermont Ferrand | Clermont-Ferrand, 63003, France Lise Laclautre Damien Bouvier Principal Investigator
Centre Jean Perrin | Clermont-Ferrand, France lise Laclautre Marie Batisse Principal Investigator
Location Countries

France

Verification Date

2021-05-01

Responsible Party

Type: Sponsor

Keywords
Has Expanded Access No
Condition Browse
Arm Group

Label: Unexplained hypophosphatemia

Description: Collection of additional blood volume (approximately 10 mL) during blood tests provided as part of the usual medical care.

Acronym IFEH
Study Design Info

Observational Model: Cohort

Time Perspective: Prospective

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact [email protected]. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Research News